Inflammatory myopathy

Jump to navigation Jump to search

Inflammatory Myopathy

Home

Overview

Classification

Differentiating Inflammatory myopathy from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Inflammatory myopathies are a group of disorders that involve muscles and skin. Latest classification by European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) classified idiopathic inflammatory myopathy into 6 subtypes including polymyositis, dermatomyositis, inclusion body myositis, immune−mediated necrotizing myopathies (IMNM), amyopathic dermatomyositis, and juvenile dermatomyositis. It is considered that autoimmunity has a major role on pathogenesis of these diseases. Inflammatory myopathies might present with involvement of other organs including blood vessels, lungs, connective tissue, solid organs, or joints. Inflammatory myopathies are rare and may affect both children and adults. There are no definitive therapy for inflammatory myopathies. However, corticosteroids and symptomatic therapy are the first line treatment for inflammatory myopathies. Immunosuppressants might be used in patients who have recurrent or resistant symptoms. Lifestyle modifications including physical therapy, watching diet, and controlling weight are recommended. The prognosis of inflammatory myopathies varies and it depends on extramuscular involvement, early initiation of treatment, and presence of certain autoantibodies. Diagnosis is usually made by biopsy and detecting inflammation on muscle or skin biopsies.

Classification

The 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathy Score
Variable No muscle biopsy With muscle biopsy
Age of onset ≥ 18 and < 40 years 1.3 1.5
Age of onset ≥ 40 years 2.1 2.2
Objective symmetric weakness, usually progressive, of the proximal upper extremities 0.7 0.7
Objective symmetric weakness, usually progressive, of the proximal lower extremities 0.8 0.5
Neck flexors are relatively weaker than neck extensors 1.9 1.6
In the legs, proximal muscles are relatively weaker than distal muscles 0.9 1.2
Heliotrope rash 3.1 3.2
Gottron’s papules 2.1 2.7
Gottron’s sign 3.3 3.7
Dysphagia or esophageal dysmotility 0.7 0.6
Anti−Jo1 autoantibody present 3.9 3.8
Elevated serum levels of CK or LDH* or ASAT/AST/SGOT* or ALAT/ALT/SGPT* 1.3 1.4
Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibers on muscle biopsy 1.7
Perifascicular atrophy 1.9
Rimmed vacuoles 3.1

Probability of IIM including muscle biopsy=1/[1+exponential (5.33–score)]

Probability of IIM without muscle biopsy=1/[1+exponential (6.49–score)]

To use the calculator to assess the probability of IIM, click here.

Classification algorithm for subgroups of IIM

Abbreviation: ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; IIM, idiopathic inflammatory myopathies;

 
 
 
 
 
 
 
 
 
 
 
 
A patient meets the EULAR/ACR classification criteria for IIM (probability of IIM ≥55%)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age of onset 0-17 years old
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Skin manifestations include Heliotrope rash, Gottron's papules, or Gottron's sign
 
 
 
 
 
 
 
 
Skin manifestations include Heliotrope rash, Gottron's papules, or Gottron's sign
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
Yes
 
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical features include finger flexor weakness, or no treatment response,
or Muscle biopsy includes rimmed vacuoles
 
 
 
 
 
Muscle weakness*
 
 
Juvenile myositis other than juvenile dermatomyositis
 
Juvenile dermatomyositis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymyositis,
or immune-mediated necrotizing myopathy
 
Inclusion body myositis
 
Amyopathic dermatomyositis
 
Dermatomyositis
 

* Muscle weakness manifested as objective progressive symmetric muscle weakness of proximal upper or lower extremities, neck flexors relatively weaker than extensors, or in the legs proximal muscles relatively weaker than distal

Differentiating Inflammatory Myopathy from other Diseases

Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Dermatomyositis[6][7] 40s−50s

Can affect children

Proximal + + +
  • ↑↑
  • Perimysial mononuclear infiltrate
Polymyositis[8] > 18 years Proximal + + +
  • N/A
  • N/A
  • ↑↑
  • Endomysial mononuclear infiltrate
  • Patchy necrosis
Inclusion body myositis[9] 50s Proximal

& distal

  • N/A
  • Antibodies to cytoplasmic 5'−nucleotidase
  • ↑↑
Immune−mediated necrotizing myopathies (IMNM)[10][11] 30s−70s Proximal
  • N/A
  • ↑↑↑
  • Minimal or no inflammatory infiltrates and marked muscle necrosis
Amyopathic dermatomyositis[12] 40s−60s
  • Rash
  • Pruritus
  • Photosensitivity
  • N/A
  • Heliotrope rash on face and hands
  • Gottron's sign ( violaceous scaly eruption )
  • Normal
  • Normal
  • Normal
  • Normal
Fibromyalgia[13] 40−50s Generalized +
  • Normal
  • Normal
  • Normal
  • Normal
Polymyalgia Rheumatica[14] 50s Diffuse + + +
  • History of joints stiffness, worse in the morning
  • Restricted shoulder motion
  • Normal
  • Normal
  • Normal
Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram

References

  1. Leclair V, Lundberg IE (March 2018). "New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter". Curr Rheumatol Rep. 20 (4): 18. doi:10.1007/s11926-018-0726-4. PMC 5857275. PMID 29550929.
  2. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (December 2017). "2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups". Ann. Rheum. Dis. 76 (12): 1955–1964. doi:10.1136/annrheumdis-2017-211468. PMID 29079590.
  3. Hilton-Jones, David (2011). "Observations on the classification of the inflammatory myopathies". La Presse Médicale. 40 (4): e199–e208. doi:10.1016/j.lpm.2010.10.035. ISSN 0755-4982.
  4. Benveniste, Olivier; Léger, Jean-Marc (2011). "Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011". La Presse Médicale. 40 (4): e197–e198. doi:10.1016/j.lpm.2011.02.002. ISSN 0755-4982.
  5. Lundberg, Ingrid E.; Tjärnlund, Anna; Bottai, Matteo; Werth, Victoria P.; Pilkington, Clarissa; de Visser, Marianne; Alfredsson, Lars; Amato, Anthony A.; Barohn, Richard J.; Liang, Matthew H.; Singh, Jasvinder A.; Aggarwal, Rohit; Arnardottir, Snjolaug; Chinoy, Hector; Cooper, Robert G.; Dankó, Katalin; Dimachkie, Mazen M.; Feldman, Brian M.; Garcia-De La Torre, Ignacio; Gordon, Patrick; Hayashi, Taichi; Katz, James D.; Kohsaka, Hitoshi; Lachenbruch, Peter A.; Lang, Bianca A.; Li, Yuhui; Oddis, Chester V.; Olesinska, Marzena; Reed, Ann M.; Rutkowska-Sak, Lidia; Sanner, Helga; Selva-O'Callaghan, Albert; Song, Yeong-Wook; Vencovsky, Jiri; Ytterberg, Steven R.; Miller, Frederick W.; Rider, Lisa G. (2017). "2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups". Arthritis & Rheumatology. 69 (12): 2271–2282. doi:10.1002/art.40320. ISSN 2326-5191.
  6. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  7. Lundberg, I.; Chung, Y.-L. (2000). "Treatment and investigation of idiopathic inflammatory myopathies". Rheumatology. 39 (1): 7–17. doi:10.1093/rheumatology/39.1.7. ISSN 1462-0332.
  8. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  9. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  10. Basharat, Pari; Christopher-Stine, Lisa (2015). "Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management". Current Rheumatology Reports. 17 (12). doi:10.1007/s11926-015-0548-6. ISSN 1523-3774.
  11. Bergua, C.; Chiavelli, H.; Simon, J. P.; Boyer, O.; Jouen, F.; Stenzel, W.; Martinet, J. (2016). "Immune-mediated necrotizing myopathy". Zeitschrift für Rheumatologie. 75 (2): 151–156. doi:10.1007/s00393-015-0029-3. ISSN 0340-1855.
  12. Olsen NJ, Park JH, King LE (August 2001). "Amyopathic dermatomyositis". Curr Rheumatol Rep. 3 (4): 346–51. PMID 11470054.
  13. Ohara N, Katada S, Yamada T, Mezaki N, Suzuki H, Suzuki A, Hanyu O, Yoneoka Y, Kawachi I, Shimohata T, Kakita A, Nishizawa M, Sone H (2016). "Fibromyalgia in a Patient with Cushing's Disease Accompanied by Central Hypothyroidism". Intern. Med. 55 (21): 3185–3190. doi:10.2169/internalmedicine.55.5926. PMC 5140872. PMID 27803417.
  14. Myklebust G, Gran JT (1996). "A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis". Br J Rheumatol. 35 (11): 1161–8. PMID 8948307.